UK: Patenting computer-implemented inventions

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

UK: Patenting computer-implemented inventions

In recent years, machine learning and so-called 'artificial intelligence' systems have once again come into the spotlight. As ever, patent law both in the UK and around the world has developed to keep pace with and encourage these emerging technologies.

The UK Intellectual Property Office (UKIPO) and the UK courts are often guided by decisions of the European Patent Office (EPO). However, when considering the patentability of computer-implemented inventions both the EPO and the UKIPO have forged their own path.

In the UK, the patentability of computer-implemented inventions is viewed through the framework of the Aerotel case. Here, the patentability of a computer-implemented invention is decided by first determining the actual inventive contribution defined by the claims of a patent application in view of the existing technology. Subsequently, in a second stage, this inventive contribution is considered to determine whether it falls solely within the subject matter excluded from patentability, for example the contribution defined by the claims is purely a business or mathematical method.

In a final stage, the inventive contribution is assessed to determine if it is technical in nature, for example by effecting a process which occurs outside a computer. If this final criterion is satisfied, the patentability of the claimed subject matter will be viewed favourably by the UKIPO.

On the other hand, the EPO takes an approach whereby the recitation of a single technical feature, even a generic computer system, in a patent claim is sufficient to draw the claim out of the realm of excluded subject matter. However, once this first hurdle is overcome, the EPO will then disregard any non-technical features, such as presentations of information or methods of doing business, included in the claims and consider the novelty or inventiveness of the remaining subject matter. If after disregarding any non-technical features all that remains is a generic computer system, the claim will lack novelty or an inventive step.

In practice, while the methodology used to assess the patentability of computer-implemented inventions differs between the EPO and the UKIPO, both approaches tend to arrive at a similar conclusion. However, to ensure the best chance of success before both the EPO and the UKIPO, it is vital that any draft patent application directed towards a computer-implemented invention discusses the real world effects of the invention in detail.

gibb.jpg

Thomas Gibb


Chapman IPKings Park House22 Kings Park RoadSouthampton SO15 2ATUnited KingdomTel: +44 1962 600 500  info@chapmanip.com  www.chapmanip.com

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article